DE60133323D1 - Cardioprotektive Phosphonate - Google Patents
Cardioprotektive PhosphonateInfo
- Publication number
- DE60133323D1 DE60133323D1 DE60133323T DE60133323T DE60133323D1 DE 60133323 D1 DE60133323 D1 DE 60133323D1 DE 60133323 T DE60133323 T DE 60133323T DE 60133323 T DE60133323 T DE 60133323T DE 60133323 D1 DE60133323 D1 DE 60133323D1
- Authority
- DE
- Germany
- Prior art keywords
- hydroxymethyl
- hydroxy
- methyl
- cardioprotective
- phosphonates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 title 1
- 230000003293 cardioprotective effect Effects 0.000 title 1
- -1 for example Chemical class 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- SXYOXKZQHUAGLZ-UHFFFAOYSA-N 2-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methyl]propanedioic acid Chemical class CC1=NC=C(CC(C(O)=O)C(O)=O)C(CO)=C1O SXYOXKZQHUAGLZ-UHFFFAOYSA-N 0.000 abstract 1
- PSEUCWBUARUAMP-UHFFFAOYSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;propanedioic acid Chemical class OC(=O)CC(O)=O.CC1=NC=C(CO)C(CO)=C1O PSEUCWBUARUAMP-UHFFFAOYSA-N 0.000 abstract 1
- HSBSNPYTEWODSO-UHFFFAOYSA-N P(O)(O)=O.N1=C(C)C(O)=C(CO)C(CO)=C1 Chemical class P(O)(O)=O.N1=C(C)C(O)=C(CO)C(CO)=C1 HSBSNPYTEWODSO-UHFFFAOYSA-N 0.000 abstract 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
- C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Credit Cards Or The Like (AREA)
- Pyridine Compounds (AREA)
- Materials For Medical Uses (AREA)
- Adhesives Or Adhesive Processes (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18589900P | 2000-02-29 | 2000-02-29 | |
US185899P | 2000-02-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60133323D1 true DE60133323D1 (de) | 2008-04-30 |
DE60133323T2 DE60133323T2 (de) | 2009-03-05 |
Family
ID=22682882
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60133323T Expired - Fee Related DE60133323T2 (de) | 2000-02-29 | 2001-02-28 | Cardioprotektive Phosphonate |
DE60110054T Expired - Fee Related DE60110054T2 (de) | 2000-02-29 | 2001-02-28 | Cardioprotektive phosphonate |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60110054T Expired - Fee Related DE60110054T2 (de) | 2000-02-29 | 2001-02-28 | Cardioprotektive phosphonate |
Country Status (11)
Country | Link |
---|---|
US (5) | US6605612B2 (de) |
EP (1) | EP1268498B1 (de) |
JP (1) | JP2003525303A (de) |
AT (2) | ATE389662T1 (de) |
AU (2) | AU3718501A (de) |
CA (1) | CA2401655C (de) |
DE (2) | DE60133323T2 (de) |
DK (1) | DK1268498T3 (de) |
ES (2) | ES2240419T3 (de) |
PT (1) | PT1268498E (de) |
WO (1) | WO2001064692A1 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001003682A2 (en) * | 1999-07-13 | 2001-01-18 | Medicure Inc. | Use of pyridoxin derivatives for the treatment of diabetes and related complications |
EP1210117A2 (de) | 1999-08-24 | 2002-06-05 | Medicure International Inc. | Zusammensetzungen zur behandlung von kardiovaskularen krankheiten die pyridoxal-derivate und kardiovaskuläre mittel enthalten |
US7442689B2 (en) * | 2000-02-29 | 2008-10-28 | Medicure International Inc. | Cardioprotective phosphonates and malonates |
EP1278526A2 (de) * | 2000-03-28 | 2003-01-29 | Medicure International Inc. | Behandlung von zerebrovaskulären erkrankungen |
US6897228B2 (en) * | 2000-07-07 | 2005-05-24 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: new uses |
US20040121988A1 (en) * | 2001-03-28 | 2004-06-24 | Medicure International Inc. | Treatment of cerebrovascular disease |
US6822018B2 (en) * | 2002-02-15 | 2004-11-23 | Delphi Technologies, Inc. | Thermally-conductive electrically-insulating polymer-base material |
US20040186077A1 (en) * | 2003-03-17 | 2004-09-23 | Medicure International Inc. | Novel heteroaryl phosphonates as cardioprotective agents |
WO2004084895A2 (en) * | 2003-03-27 | 2004-10-07 | Medicure, Inc. | Modulation of cell death |
WO2004084910A1 (en) * | 2003-03-27 | 2004-10-07 | Medicure Inc. | Compositions for treating angina |
WO2005060975A1 (en) * | 2003-12-23 | 2005-07-07 | Medicure International Inc. | Combination therapies employing a composition comprising a hmg coa reductase inhibitor and a vitamin b6 related compound |
DE602005025755D1 (de) * | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
CA2570048A1 (en) * | 2004-07-07 | 2006-01-12 | Medicure International Inc. | Combination therapies employing platelet aggregation drugs |
CA2572815A1 (en) * | 2004-07-09 | 2006-01-19 | Medicure International Inc. | Combination therapies employing nicotinic acid derivatives or fibric acid derivatives |
US20070060549A1 (en) * | 2004-08-10 | 2007-03-15 | Friesen Albert D | Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
EP1796684A1 (de) * | 2004-09-10 | 2007-06-20 | Medicure International Inc. | Mit vitamin b6 in zusammenhang stehende verbindungen und verfahren zur erholung von trauma |
WO2006050598A1 (en) * | 2004-10-28 | 2006-05-18 | Medicure International Inc. | Dual antiplatelet/anticoagulant pyridoxine analogs |
US7459468B2 (en) * | 2004-10-28 | 2008-12-02 | Medicure International, Inc. | Aryl sulfonic pyridoxines as antiplatelet agents |
US20060094749A1 (en) * | 2004-10-28 | 2006-05-04 | Medicure International Inc. | Substituted pyridoxines as anti-platelet agents |
EP1827455A1 (de) * | 2004-11-26 | 2007-09-05 | Medicure International Inc. | Neue formulierung von pyridoxal 5'-phosphat und herstellungsverfahren |
EP1853275A4 (de) * | 2004-11-26 | 2008-09-10 | Medicure Int Inc | FORMULIERUNGEN AUS PYRIDOXAL-5ý-PHOSPHAT UND HERSTELLUNGSVERFAHREN |
JP2008526783A (ja) * | 2005-01-05 | 2008-07-24 | メディキュア・インターナショナル・インコーポレーテッド | トリグリセリドレベルを調節するための化合物及び方法 |
CA2503087A1 (en) * | 2005-03-30 | 2006-09-30 | Medicure International Inc. | Intravenous formulations of pyridoxal 5'-phosphate and method of preparation |
AU2006317440A1 (en) * | 2005-11-28 | 2007-05-31 | Medicure International Inc. | Selected dosage for the treatment of cardiovascular and related pathologies |
US20070249562A1 (en) * | 2006-04-25 | 2007-10-25 | Friesen Albert D | Treatment of atrial fibrillation |
US20100035296A1 (en) * | 2007-01-04 | 2010-02-11 | Anat Shirvan | Compounds and methods for detection of cells |
WO2014025352A1 (en) * | 2012-08-09 | 2014-02-13 | Empire Technology Development Llc | Flame retardant nylon |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3206463A (en) | 1965-09-14 | Pyridoxine aspartate and its process of preparation | ||
FR846376A (fr) | 1938-08-23 | 1939-09-15 | Appareillage de navigation aérienne et de bombardement aérien | |
GB966805A (en) | 1961-05-15 | 1964-08-19 | Merck & Co Inc | Process for the preparation of 2-methyl-3-hydroxypyridines |
NL280553A (de) | 1962-07-05 | |||
FR5552M (de) | 1966-04-28 | 1967-11-20 | ||
FR5801M (de) | 1966-06-27 | 1968-02-19 | ||
GB1228142A (de) | 1967-03-31 | 1971-04-15 | ||
FR6453M (de) | 1967-06-13 | 1968-11-12 | ||
DE1802162A1 (de) | 1967-10-16 | 1969-04-30 | Tanabe Seiyaku Co | Neue N-Pyridylmethyliden-homocystein-thiolacton-Verbindung und Verfahren zu ihrer Herstellung |
ES367284A1 (es) | 1968-05-16 | 1971-04-01 | Merck Ag E | Procedimiento para la obtencion de preparados de vitaminas solidos. |
ES360566A1 (es) | 1968-11-22 | 1970-10-16 | Made Labor Sa | Un metodo de obtencion de alfa-cetoglutarato de piridoxina y sus derivados. |
GB1236531A (en) | 1969-02-12 | 1971-06-23 | Soc D Etudes Prod Chimique | Adenin derivative |
US3910921A (en) | 1970-01-08 | 1975-10-07 | Soc D Etudes Prod Chimique | Papaverine monopyridoxal phosphate |
GB1297080A (de) | 1970-04-17 | 1972-11-22 | ||
FR2101010A1 (en) | 1970-08-06 | 1972-03-31 | Lyocentre | Sparteine mono-and dipyridoxinates and prepn - as tonics for cardiova disorders |
GB1493993A (en) | 1975-05-16 | 1977-12-07 | Howard A | Dietary supplement and dietary methods employing said supplement for the treatment of obesity |
US4036844A (en) | 1972-04-04 | 1977-07-19 | Beecham Group Limited | Aryloxypyridines |
US4053607A (en) | 1972-04-04 | 1977-10-11 | Beecham Group Limited | Aryloxypyridine for treating hyperglycaemia |
GB1360536A (en) | 1972-04-25 | 1974-07-17 | Soc D Etudes Prod Chimique | Pyridoxyl-l-aspartic acid salt |
BE790118A (fr) | 1972-10-09 | 1973-02-01 | Made Labor Sa | Derives de l'alpha-cetoglutarate de pyridoxal et de pyridoxamine, |
US4032534A (en) | 1973-03-22 | 1977-06-28 | Ferlus-Chimie S.A. | Certain 2-(2-thioethyl)thiazolidine-4-carboxylic acids |
FR2255883A1 (en) | 1973-12-28 | 1975-07-25 | Centre Etd Ind Pharma | Clofibric acid-vitamin B6 compsns. - with synergistic hypocholesterolaemic and normolipaemic activity |
FR2275209A1 (fr) | 1974-06-21 | 1976-01-16 | Synthelabo | Nouveaux esters cetoniques, leurs sels, leur preparation et les medicaments qui les renferment |
FR2276048A1 (fr) | 1974-06-27 | 1976-01-23 | Synthelabo | Nouveaux esters du cyclohexanol, leurs sels, leur preparation et les medicaments qui les renferment |
DE2461742C2 (de) | 1974-12-28 | 1983-01-27 | Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt | Pyridoxin-5'-phosphorsäureester-Derivate sowie deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
GB1525885A (en) | 1976-05-11 | 1978-09-20 | Soc D Etudes Prod Chimique | Vincamine salt of pyridoxal phosphate |
JPS5417130A (en) | 1977-07-08 | 1979-02-08 | Chugai Pharmaceut Co Ltd | Remedy for cardio-vasocular diseases |
BE863754A (fr) | 1978-02-08 | 1978-05-29 | Dechamps Pierre | Nouveaux derives de la vincamine utilisables comme regulateurs de la circulation cerebrale |
FR2428640A1 (fr) | 1978-06-12 | 1980-01-11 | Parcor | Derives de pyridoxine, leur procede de preparation et leur application therapeutique |
US4167562A (en) | 1978-08-28 | 1979-09-11 | Evers H Ray | Method and composition for treating arteriosclerosis |
IL62602A (en) | 1980-05-19 | 1984-06-29 | Labaz Sanofi Nv | Pyridoxine derivatives,their preparation and pharmaceutical compositions containing them |
IT1141070B (it) | 1980-09-22 | 1986-10-01 | Luso Farmaco Inst | Impiego dell'alfa-chetoglutarato di piridossina nella profilassi della iperlattacidemia |
US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
US4528197A (en) | 1983-01-26 | 1985-07-09 | Kabivitrum Ab | Controlled triglyceride nutrition for hypercatabolic mammals |
IN160104B (de) | 1983-04-05 | 1987-06-27 | Scras | |
US4735950A (en) | 1983-04-05 | 1988-04-05 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S) | Furo-(3,4-C)-pyridine derivatives and therapeutic composition containing the same |
US4515771A (en) | 1983-04-11 | 1985-05-07 | Fine Daniel H | Composition and method for the preventative treatment of dental disease and apparatus for dispensing said composition |
GB8330517D0 (en) | 1983-11-16 | 1983-12-21 | Scras | 6-vinyl-furo-(3,4-c)pyridine derivatives |
GB8330658D0 (en) | 1983-11-17 | 1983-12-29 | Scras | 7-carboxymethoxy-furo-(3,4-c)-pyridine derivatives |
IT1212792B (it) | 1983-11-30 | 1989-11-30 | Egidio Aldo Moja | Supplemento dietetico e alimento preconfezionato che lo contiene procedimento di preparazione e metodo di somministrazione |
US5130324A (en) | 1984-03-19 | 1992-07-14 | The Rockefeller University | 2-alkylidene-aminoguanidines and methods of use therefor |
US5272165A (en) | 1984-03-19 | 1993-12-21 | The Rockefeller University | 2-alkylidene-aminoguanidines and methods of use therefor |
CH664158A5 (fr) | 1984-07-18 | 1988-02-15 | Symphar Sa | Derives propylidenediphosphonates-1,3 substitues en position 2, leur procede de preparation et compositions pharmaceutiques les contenant. |
US4567179A (en) | 1984-10-11 | 1986-01-28 | Pfizer, Inc. | Antiinflammatory salts of piroxicam |
DE3519693A1 (de) | 1985-06-01 | 1987-01-02 | Basf Ag | Pyridin-derivate, ihre herstellung und verwendung |
US4837239A (en) | 1985-08-23 | 1989-06-06 | Syntex (U.S.A.) Inc. | Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins |
US5053396A (en) | 1985-08-27 | 1991-10-01 | Blass David H | Therapeutic composition |
US4735956A (en) | 1985-09-13 | 1988-04-05 | Merck & Co., Inc. | Certain 1,4-dihydro-2,6-di-lower hydrocarbyl-4-heterocyclic-3,5-pyridine dicarboxylates which are useful as calcium channel blockers |
US4605741A (en) | 1985-11-13 | 1986-08-12 | Lisapharma Spa | Pharmaceutically active salt derivative of 3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde phosphate |
DE3634016A1 (de) | 1986-04-17 | 1987-10-29 | Lohmann Gmbh & Co Kg | Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung |
US5210083A (en) | 1986-07-17 | 1993-05-11 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Pharmaceutical compositions |
US5563126A (en) | 1986-11-20 | 1996-10-08 | Metabolite Laboratories | Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6 |
US5254572A (en) | 1987-11-27 | 1993-10-19 | Vesta Medicines (Pty) Ltd. | Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed |
US5631271A (en) | 1986-11-29 | 1997-05-20 | Serfontein; Willem J. | Methods and preparations for the treatment and prophylaxis of metabolic disturbances |
NZ222664A (en) | 1986-11-29 | 1990-06-26 | Vesta Med Pty Ltd | Pharmaceutical compositions containing pyridoxal as a source of vitamin b6 |
US4843071A (en) | 1986-12-05 | 1989-06-27 | Serotonin Industries Of Charleston | Method and composition for treating obesity, drug abuse, and narcolepsy |
DE3705549A1 (de) | 1987-02-18 | 1988-09-01 | Ulrich Speck | Verwendung von pyridoxin-derivaten bei der prophylaxe und therapie von hyperlipidaemien und atherosklerose |
US5288716A (en) | 1987-02-18 | 1994-02-22 | Ulrich Speck | Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis |
SE8701662L (sv) | 1987-04-22 | 1988-10-23 | Gelder Nico M Van | Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna |
US5213813A (en) | 1987-05-29 | 1993-05-25 | The University Of Vermont | Pyridoxal-5'-phosphate as an in vitro blood platelet stabilizer |
ES2043897T3 (es) | 1988-01-28 | 1994-01-01 | Koeltringer Peter | Preparado de combinacion, en especial para el tratamiento de enfermedades de las celulas nerviosas. |
NO179479C (no) | 1988-03-11 | 1996-10-16 | Teikoku Seiyaku Kk | Fremgangsmåte for fremstilling av et intravaginalt farmasöytisk preparat |
US5254557A (en) | 1988-05-09 | 1993-10-19 | Beecham Group P.L.C. | Compound and treatment |
US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
US5001115A (en) | 1989-05-17 | 1991-03-19 | University Of Florida | Prodrugs of biologically active hydroxyaromatic compounds |
GB8918368D0 (en) | 1989-08-11 | 1989-09-20 | Amco Chemie Gmbh | Compositions for treating obstructive airways disease |
DE4016963A1 (de) | 1990-05-25 | 1991-11-28 | Steigerwald Arzneimittelwerk | Verwendung von magnesium-pyridoxal-5'-phosphat-glutaminat zur verhinderung von erkrankungen, die sich infolge von gefaessschaeden ergeben |
US5385937A (en) | 1991-04-10 | 1995-01-31 | Brigham & Women's Hospital | Nitrosation of homocysteine as a method for treating homocysteinemia |
GB2254556B (en) | 1991-04-11 | 1995-04-12 | Fisons Plc | Formulations containing linolenic acid |
EP0586523A4 (en) | 1991-05-15 | 1995-11-29 | Univ Yale | Determination of prodrugs metabolizable by the liver and therapeutic use thereof |
FR2678622B1 (fr) | 1991-07-03 | 1994-11-18 | Adir | Nouveaux complexes de vanadium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
WO1993013660A1 (en) | 1992-01-06 | 1993-07-22 | Health Maintenance Programs, Inc. | Pharmaceutically active antioxydant containing composition and the method of its use to prevent and treat restenosis following angioplasty |
DE69327402T2 (de) | 1992-06-12 | 2000-05-04 | Albert Einstein College Of Medicine Of Yeshiva University, Bronx | Vorbeugung und behandlung der peripheren neuropathie |
US5420112A (en) | 1992-06-12 | 1995-05-30 | Lewis; Michael E. | Prevention and treatment of peripheral neuropathy |
US5330743A (en) | 1992-11-12 | 1994-07-19 | Magnetic Research, Inc. | Aminosaccharide contrast agents for magnetic resonance images |
US5795873A (en) | 1992-12-29 | 1998-08-18 | Metabolite Laboratories, Inc. | Method for treatment and prevention of deficiencies of vitamins B12, folic acid and B6 |
TW268948B (de) | 1993-04-02 | 1996-01-21 | Senju Pharma Co | |
DE4344751A1 (de) | 1993-12-28 | 1995-06-29 | Carl Heinrich Dr Weischer | Neue Vitamin B6-Derivate und deren Herstellung und Verwendung als Arzneimittel und als Kosmetika |
US5504090A (en) | 1994-03-30 | 1996-04-02 | Trustees Of The University Of Pennsylvania | Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury |
RU2180852C2 (ru) | 1994-12-12 | 2002-03-27 | Омерос Медикл Системс, Инк. | Ингибирующий раствор и способ подавления боли, воспаления или спазма |
US5569459A (en) | 1995-02-15 | 1996-10-29 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders |
US5733916A (en) | 1995-03-24 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists |
US5874443A (en) | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
US5833998A (en) | 1995-11-06 | 1998-11-10 | The Procter & Gamble Company | Topical compositions for regulating the oily/shiny appearance of skin |
US5733884A (en) | 1995-11-07 | 1998-03-31 | Nestec Ltd. | Enteral formulation designed for optimized wound healing |
US5874420A (en) | 1995-12-26 | 1999-02-23 | Allegheny University Of The Health Sciences | Process for regulating vagal tone |
US5847008A (en) | 1996-02-02 | 1998-12-08 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
US5859051A (en) | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
US5834446A (en) | 1996-06-21 | 1998-11-10 | Queen's University At Kingston | Nerve process growth modulators |
JPH10158244A (ja) | 1996-12-02 | 1998-06-16 | Kissei Pharmaceut Co Ltd | 5−アミノアルキル−4−アミノメチル−3−ヒドロキシピリジン誘導体およびそれらを含有するメイラード反応阻害剤 |
GB9626615D0 (en) * | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
US5770215A (en) | 1997-01-06 | 1998-06-23 | Moshyedi; Emil Payman | Multivitamin/vascular occlusion inhibiting composition |
US5804594A (en) | 1997-01-22 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for improving wrinkles and other skin conditions |
US5944020A (en) | 1997-02-25 | 1999-08-31 | Cypros Pharmaceutical Corp. | Use of fructose-1 6-diphosphate as an inotrope drug after cardiopulmonary bypass surgery |
US5888514A (en) | 1997-05-23 | 1999-03-30 | Weisman; Bernard | Natural composition for treating bone or joint inflammation |
EP0891719A1 (de) | 1997-07-14 | 1999-01-20 | N.V. Nutricia | Narungszusammensetzungen mit Gehalt an Methionin |
US6051587A (en) * | 1998-04-16 | 2000-04-18 | Medicure, Inc. | Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein |
CA2254528C (en) * | 1998-07-09 | 2007-07-17 | University Of Manitoba | Treatment of ischemia reperfusion injury and treatment of cellular dysfunction including arrhythmia and heart failure subsequent to myocardial infarction |
US6043259A (en) | 1998-07-09 | 2000-03-28 | Medicure Inc. | Treatment of cardiovascular and related pathologies |
-
2001
- 2001-02-28 PT PT01909391T patent/PT1268498E/pt unknown
- 2001-02-28 ES ES01909391T patent/ES2240419T3/es not_active Expired - Lifetime
- 2001-02-28 JP JP2001564188A patent/JP2003525303A/ja not_active Ceased
- 2001-02-28 AT AT05075063T patent/ATE389662T1/de not_active IP Right Cessation
- 2001-02-28 AU AU3718501A patent/AU3718501A/xx active Pending
- 2001-02-28 AT AT01909391T patent/ATE293119T1/de not_active IP Right Cessation
- 2001-02-28 CA CA2401655A patent/CA2401655C/en not_active Expired - Fee Related
- 2001-02-28 DK DK01909391T patent/DK1268498T3/da active
- 2001-02-28 ES ES05075063T patent/ES2305994T3/es not_active Expired - Lifetime
- 2001-02-28 EP EP01909391A patent/EP1268498B1/de not_active Expired - Lifetime
- 2001-02-28 DE DE60133323T patent/DE60133323T2/de not_active Expired - Fee Related
- 2001-02-28 WO PCT/CA2001/000265 patent/WO2001064692A1/en active IP Right Grant
- 2001-02-28 AU AU2001237185A patent/AU2001237185B2/en not_active Ceased
- 2001-02-28 US US09/795,689 patent/US6605612B2/en not_active Expired - Fee Related
- 2001-02-28 DE DE60110054T patent/DE60110054T2/de not_active Expired - Fee Related
-
2002
- 2002-10-28 US US10/282,325 patent/US7105673B2/en not_active Expired - Fee Related
- 2002-10-28 US US10/282,328 patent/US6780997B2/en not_active Expired - Fee Related
- 2002-10-28 US US10/282,326 patent/US6667315B2/en not_active Expired - Fee Related
-
2003
- 2003-02-28 US US10/377,507 patent/US6867215B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ES2305994T3 (es) | 2008-11-01 |
US20020010158A1 (en) | 2002-01-24 |
AU2001237185B2 (en) | 2006-02-02 |
US20030120074A1 (en) | 2003-06-26 |
PT1268498E (pt) | 2005-07-29 |
US20030114677A1 (en) | 2003-06-19 |
DK1268498T3 (da) | 2005-08-08 |
DE60133323T2 (de) | 2009-03-05 |
ATE389662T1 (de) | 2008-04-15 |
EP1268498A1 (de) | 2003-01-02 |
ES2240419T3 (es) | 2005-10-16 |
ATE293119T1 (de) | 2005-04-15 |
US6667315B2 (en) | 2003-12-23 |
US6605612B2 (en) | 2003-08-12 |
US20030181422A1 (en) | 2003-09-25 |
CA2401655C (en) | 2010-06-22 |
JP2003525303A (ja) | 2003-08-26 |
US20030114678A1 (en) | 2003-06-19 |
EP1268498B1 (de) | 2005-04-13 |
DE60110054D1 (en) | 2005-05-19 |
US6780997B2 (en) | 2004-08-24 |
WO2001064692A1 (en) | 2001-09-07 |
US6867215B2 (en) | 2005-03-15 |
US7105673B2 (en) | 2006-09-12 |
DE60110054T2 (de) | 2006-03-09 |
CA2401655A1 (en) | 2001-09-07 |
AU3718501A (en) | 2001-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60133323D1 (de) | Cardioprotektive Phosphonate | |
SE0301010D0 (sv) | Novel compounds | |
SE0301009D0 (sv) | Novel compounds | |
EA200601553A1 (ru) | Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды | |
TW200519075A (en) | Novel compounds | |
EA200601554A1 (ru) | Замещенные индол-о-глюкозиды | |
UA86599C2 (en) | Substituted benzimidazole-, benztriazole- and benzimidazolone-о-glucosides | |
TW200612892A (en) | Novel compounds | |
RS20060320A (en) | Substituted indazole-o-glucosides | |
NO20055590L (no) | Kinaseinhiberende fosfonatanaloger | |
WO2005002626A3 (en) | Therapeutic phosphonate compounds | |
TW200630336A (en) | Novel compounds | |
TW200621690A (en) | Novel compounds | |
ATE490788T1 (de) | Antivirale phosphonate analoge | |
DE60009511D1 (de) | Nematizide trifluorbutene | |
NO20064347L (no) | Substituerte 1,2,3,4-tetrahydroisokinolinderivater | |
ATE433447T1 (de) | Pyrimiidinverbindungen | |
MY138708A (en) | Biaryloxymethylarenecarboxylic acids | |
NO20055612L (no) | Anti-inflammatoriske fosfonatforbindelser | |
EP1831239B8 (de) | Verfahren zur herstellung von 17-hydroxy-6 beta, 7 beta, 15 beta,16 beta-bismethylen-17alpha-pregn-4-en-3-on-21-carbonsäure gamma-lacton und schlüsselzwischenprodukte für dieses verfahren | |
DK0973544T3 (da) | Immuntolerant prothrombinkomplekspræparat | |
CY1105275T1 (el) | Ενωσεις υποκατεστημενης γ-λακτονης ως ανταγωνισται - νμda | |
MXPA03008801A (es) | Aril oxima-piperazinas utiles como antagonistas de ccr5. | |
WO2005016371A8 (en) | IMPROVED RECOMBINANT HUMAN INTERFERON-BETA-1b POLYPEPTIDES | |
TW200505872A (en) | Hepatitis C virus inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |